|
|
||||||||
Nitric oxide mediates a wide array of cellular functions in many tissues. It is generated by three known isoforms of nitric oxide synthases (NOS). Recently, the endothelial isoform, NOSIII, was shown to be abundantly expressed in the rat thyroid gland and its expression increased in goitrous glands.
In this study, we analyzed whether NOSIII is expressed in human thyroid tissue and whether levels of expression vary in different states of thyroid gland function. Semiquantitative RT-PCR was used to assess variations in NOSIII gene expression in seven patients with Graves' disease, one with a TSH-receptor germline mutation and six hypothyroid patients (Hashimoto's thyroiditis). Protein expression and subcellular localization were determined by immunohistochemistry (two normal thyroids, five multinodular goiters, ten hyperthyroid patients and two hypothyroid patients).
NOSIII mRNA was detected in all samples: the levels were significantly higher in tissues from hyperthyroid patients compared with euthyroid and hypothyroid patients. NOSIII immunoreactivity was detected in vascular endothelial cells, but was also found in thyroid follicular cells. In patients with Graves' disease, the immunostaining was diffusely enhanced in all follicular cells. A more intense signal was observed in toxic adenomas and in samples obtained from a patient with severe hyperthyroidism due to an activating mutation in the TSH receptor. In multinodular goiters, large follicles displayed a weak signal whereas small proliferative follicles showed intense immunoreactivity near the apical plasma membrane. In hypothyroid patients, NOSIII immunoreactivity was barely detectable.
In summary, NOSIII is expressed both in endothelial cells and thyroid follicular cells. The endothelial localization of NOSIII is consistent with a role for nitric oxide in the vascular control of the thyroid. NOSIII expression in thyroid follicular cells and the variations in its immunoreactivity suggest a possible role for nitric oxide in thyrocyte function and/or growth.
European Journal of Endocrinology 136 649–655
This article has been cited by other articles:
![]() |
L. Fozzatti, M. L Velez, A. M Lucero, J. P Nicola, I. D Mascanfroni, D. R Maccio, C. G Pellizas, G. A Roth, and A. M Masini-Repiso Endogenous thyrocyte-produced nitric oxide inhibits iodide uptake and thyroid-specific gene expression in FRTL-5 thyroid cells J. Endocrinol., March 1, 2007; 192(3): 627 - 637. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Vargas, J. M. Moreno, R. Wangensteen, I. Rodriguez-Gomez, and J. Garcia-Estan The endocrine system in chronic nitric oxide deficiency Eur. J. Endocrinol., January 1, 2007; 156(1): 1 - 12. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-C. Gerard, M. Boucquey, M.-F. van den Hove, and I. M. Colin Expression of TPO and ThOXs in human thyrocytes is downregulated by IL-1{alpha}/IFN-{gamma}, an effect partially mediated by nitric oxide Am J Physiol Endocrinol Metab, August 1, 2006; 291(2): E242 - E253. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ortega, J. M Vila, M. D. Mauricio, G. Segarra, P. Medina, J. B Martinez-Leon, and S. Lluch Nitric oxide mediates abnormal responsiveness of thyroid arteries in methimazole-treated patients Eur. J. Endocrinol., April 1, 2005; 152(4): 551 - 556. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. A. Patel, A. Logan, J. C. Watkinson, S. Uz-Zaman, M. C. Sheppard, J. D. Ramsden, and M. C. Eggo Isolation and characterization of human thyroid endothelial cells Am J Physiol Endocrinol Metab, January 1, 2003; 284(1): E168 - E176. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Maas, E. Schwedhelm, J. Albsmeier, and R. H Boger The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function Vascular Medicine, August 1, 2002; 7(3): 213 - 225. [Abstract] [PDF] |
||||
![]() |
U. Förstermann, J.-p. Boissel, and H. Kleinert Expressional control of the `constitutive' isoforms of nitric oxide synthase (NOS I and NOS III) FASEB J, July 1, 1998; 12(10): 773 - 790. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |